» Articles » PMID: 33625877

OncoTree: A Cancer Classification System for Precision Oncology

Abstract

Purpose: Cancer classification is foundational for patient care and oncology research. Systems such as International Classification of Diseases for Oncology (ICD-O), Systematized Nomenclature of Medicine Clinical Terms (SNOMED-CT), and National Cancer Institute Thesaurus (NCIt) provide large sets of cancer classification terminologies but they lack a dynamic modernized cancer classification platform that addresses the fast-evolving needs in clinical reporting of genomic sequencing results and associated oncology research.

Methods: To meet these needs, we have developed OncoTree, an open-source cancer classification system. It is maintained by a cross-institutional committee of oncologists, pathologists, scientists, and engineers, accessible via an open-source Web user interface and an application programming interface.

Results: OncoTree currently includes 868 tumor types across 32 organ sites. OncoTree has been adopted as the tumor classification system for American Association for Cancer Research (AACR) Project Genomics Evidence Neoplasia Information Exchange (GENIE), a large genomic and clinical data-sharing consortium, and for clinical molecular testing efforts at Memorial Sloan Kettering Cancer Center and Dana-Farber Cancer Institute. It is also used by precision oncology tools such as OncoKB and cBioPortal for Cancer Genomics.

Conclusion: OncoTree is a dynamic and flexible community-driven cancer classification platform encompassing rare and common cancers that provides clinically relevant and appropriately granular cancer classification for clinical decision support systems and oncology research.

Citing Articles

Impact of genetic mutations on prognosis and chemotherapy efficacy in advanced appendiceal carcinoma: insights from the nationwide Japanese comprehensive genomic profiling test database.

Taniguchi S, Takahashi M, Chiu S, Komine K, Wakayama S, Numakura R Int J Clin Oncol. 2025; .

PMID: 40019690 DOI: 10.1007/s10147-025-02724-2.


Learning and actioning general principles of cancer cell drug sensitivity.

Carli F, Di Chiaro P, Morelli M, Arora C, Bisceglia L, De Oliveira Rosa N Nat Commun. 2025; 16(1):1654.

PMID: 39952993 PMC: 11828915. DOI: 10.1038/s41467-025-56827-5.


Personalized prediction of anticancer potential of non-oncology drugs through learning from genome derived molecular pathways.

Dong X, Liu H, Tong T, Wu L, Wang J, You T NPJ Precis Oncol. 2025; 9(1):36.

PMID: 39905223 PMC: 11794852. DOI: 10.1038/s41698-025-00813-z.


Oronasal mucosal melanoma is defined by two transcriptional subtypes in humans and dogs with implications for diagnosis and therapy.

Bowlt Blacklock K, Donnelly K, Lu Y, Del Pozo J, Glendinning L, Polton G J Pathol. 2025; 265(3):245-259.

PMID: 39828982 PMC: 11794980. DOI: 10.1002/path.6377.


Research on the influence of radiotherapy-related genes on immune infiltration, immunotherapy response and prognosis in melanoma based on multi-omics.

Shi Y, Zhao W, Ding Y, Ge X, Ju M Front Immunol. 2024; 15:1467098.

PMID: 39687627 PMC: 11647020. DOI: 10.3389/fimmu.2024.1467098.


References
1.
Thomas S, Lichtenberg T, Dang K, Fitzsimons M, Grossman R, Kundra R . Linked Entity Attribute Pair (LEAP): A Harmonization Framework for Data Pooling. JCO Clin Cancer Inform. 2020; 4:691-699. PMC: 7469618. DOI: 10.1200/CCI.20.00037. View

2.
Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky J, Desrichard A . Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371(23):2189-2199. PMC: 4315319. DOI: 10.1056/NEJMoa1406498. View

3.
Salto-Tellez M, Cree I . Cancer taxonomy: pathology beyond pathology. Eur J Cancer. 2019; 115:57-60. DOI: 10.1016/j.ejca.2019.03.026. View

4.
. AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discov. 2017; 7(8):818-831. PMC: 5611790. DOI: 10.1158/2159-8290.CD-17-0151. View

5.
Hyman D, Piha-Paul S, Won H, Rodon J, Saura C, Shapiro G . HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018; 554(7691):189-194. PMC: 5808581. DOI: 10.1038/nature25475. View